Institute for Diabetes Research, Helmholtz Diabetes Center at Helmholtz Zentrum München, Munich, Germany.
Islet Biology Exeter (IBEx), Institute of Biomedical and Clinical Sciences, University of Exeter Medical School, Exeter, UK.
Curr Diab Rep. 2018 Oct 6;18(11):124. doi: 10.1007/s11892-018-1084-3.
We provide an overview of pancreas pathology in type 1 diabetes (T1D) in the context of its clinical stages.
Recent studies of pancreata from organ donors with T1D and non-diabetic donors expressing T1D-associated autoantibodies reveal pathological changes/disease mechanisms beyond the well-known loss of β cells and lymphocytic infiltrates of the islets (insulitis), including β-cell stress, dysfunction, and viral infections. Pancreas pathology evolves through disease stages, is asynchronous, and demonstrates a chronic disease that remains active years after diagnosis. Critically, β-cell loss is not complete at onset, although young age is associated with increased severity. The recognition of multiple pathogenic alterations and the chronic nature of disease mechanisms during and after the development of T1D inform improved clinical trial design and reveal additional targets for therapeutic manipulation, in the context of an expanded time window for intervention.
我们在 1 型糖尿病(T1D)的临床分期背景下,对其胰腺病理学进行了概述。
对来自 T1D 器官供体和表达 T1D 相关自身抗体的非糖尿病供体的胰腺进行的最新研究显示,除了众所周知的β细胞丧失和胰岛的淋巴细胞浸润(胰岛炎)外,还存在病理性改变/疾病机制,包括β细胞应激、功能障碍和病毒感染。胰腺病理学通过疾病阶段演变,不同步,并表现出一种慢性疾病,在诊断后多年仍保持活跃。关键的是,β细胞丧失并非在发病时就完全发生,尽管年轻与更严重的病情相关。在 T1D 发展过程中以及之后,对多种致病改变的认识以及疾病机制的慢性性质,为临床试验设计提供了改进,并在干预的扩展时间窗口内揭示了更多的治疗靶点。